论文部分内容阅读
目的比较单用辛伐他汀与联合非诺贝特治疗高危混合性高脂血症的疗效。方法选择2009年7月—2011年6月经过8周辛伐他汀治疗,未达到全面降脂目标的高危混合性高脂血症患者169例,随机分为联合治疗组85例和辛伐他汀组84例,均治疗12周,比较两组治疗后主要血脂参数的变化情况、达标情况及安全性评价。结果两组低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C)、总胆固醇(total cholesterol,TC)、甘油三酯(totalgly cerin,TG)均有所降低,联合治疗组各项指标降幅均明显高于辛伐他汀组(均P<0.05),高密度脂蛋白胆固醇(high-densitylipoprotein cholesterol,HDL-C)均有所升高,联合治疗组升高较明显(P<0.05);LDL-C、TC、TG、HDL-C达标率联合治疗组分别为88.24%、89.41%、81.18%、90.59%,辛伐他汀组分别为58.33%、60.71%、59.52%、72.62%,两组比较差异均有统计学意义。(均P<0.05)。结论辛伐他汀联合非诺贝特能更加有效地治疗单用辛伐他汀未达到全面降脂目标的高危混合性高脂血症,具有良好的耐受性。
Objective To compare the curative effect of simvastatin and fenofibrate alone in treating high-risk mixed hyperlipidemia. Methods A total of 169 high-risk mixed hyperlipidemia patients who did not achieve the goal of total lipid-lowering after 8 weeks of simvastatin treatment from July 2009 to June 2011 were randomly divided into combined treatment group (85 cases) and simvastatin group 84 cases were treated for 12 weeks, the changes of major blood lipid parameters after treatment, compliance and safety evaluation were compared. Results The levels of low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and totalglycerin (TG) were decreased in both groups. The decline of each index in the combined treatment group (All P <0.05), high-density lipoprotein cholesterol (HDL-C) increased, and the combination therapy group increased significantly (P <0.05); LDL C, TC, TG and HDL-C in the combined treatment group were 88.24%, 89.41%, 81.18% and 90.59% respectively, and those in simvastatin group were 58.33%, 60.71%, 59.52% and 72.62% The differences were statistically significant. (All P <0.05). Conclusion Simvastatin combined with fenofibrate could be more effective in treating high-risk mixed hyperlipidemia patients who did not achieve the goal of total lipid-lowering with simvastatin alone.